Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methenamine SCHEMBL5801339 | 0.93 | EPHX2 (0.48) | SMN1; SMN2EPHX2NR1H4MAPTNPC1 | |
| SCHEMBL3604860 | 0.85 | RAB9A (0.49) | SMN1; SMN2MAPTNPC1RAB9ACA12 | |
| SCHEMBL2013987 | 0.85 | MAPT (0.49) | SMN1; SMN2EPHX2NR1H4MAPTNPC1 | |
| SCHEMBL2009888 | 0.84 | HDAC1 (0.55) | SMN1; SMN2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL16215508 | 0.84 | ALDH1A1 (0.55) | EPHX2NR1H4MAPTNPC1RAB9A | |
| SCHEMBL19331732 | 0.84 | MAPT (0.51) | SMN1; SMN2EPHX2NR1H4MAPTALOX15 | |
| SCHEMBL750357 | 0.84 | EPHX2 (0.58) | SMN1; SMN2EPHX2NR1H4MAPTNPC1 | |
| SCHEMBL2013045 | 0.84 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTNPC1RAB9AMEN1 | |
| SCHEMBL2014794 | 0.83 | L3MBTL1 (0.40) | EPHX2NR1H4MAPTCA12CA1 | |
| SCHEMBL8377749 | 0.83 | CA12 (0.44) | SMN1; SMN2EPHX2NR1H4MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064545-B1 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | PIRAMAL LIFE SCIENCES LTD (IN) | 2012-07-04 | — | — | EP | disclosed |
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| EP-2256496-A2 | Method for identifying compounds that act as insulin-sensitizers | Piramal Life Sciences Limited (IN) | 2010-12-01 | — | — | EP | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-20090318465-A1 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | Piramal Enterprises Limited (IN) | 2009-12-24 | — | — | US | disclosed |
| EP-2064545-A2 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | Piramal Life Sciences Limited (IN) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008035309-A2 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | SMN1; SMN2 4690/4885EPHX2 2113/4885NR1H4 945/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | SMN1; SMN2 4690/4885EPHX2 2113/4885NR1H4 945/4885 |
| US-20090318465-A1 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | GPR119, SLC2A4, INSR | SMN1; SMN2 3461/4885EPHX2 4236/4885NR1H4 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.